☆ 4.5 Editorial Material

More is needed to complement the available therapies of spinal muscular atrophy

FUTURE MEDICINAL CHEMISTRY (2019)

Get Full Text
Add to Collection

Journal

FUTURE MEDICINAL CHEMISTRY
Volume 11, Issue 22, Pages 2873-2876

Publisher

FUTURE SCI LTD
DOI: 10.4155/fmc-2019-0239

Keywords

AAV9; gene therapy; ISS-N1; nusinersen; oligonucleotide; spinal muscular atrophy (SMA); Spinraza; survival motor neuron (SMN)

Categories

Chemistry, Medicinal

Funding

  1. NIH [R01 NS055925, R21 NS101312]
  2. 2006 Presidential Early Career Award for Scientists and Engineers (PECASE) [US7838657]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.